TNFRSF9 and melanoma: To examine B7H6 as a potential target for CAR T therapy to AML and melanoma, we thus developed two different second-generation CAR constructs composed of the extracellular domain of the NCR NKp30 and either CD28 or CD137 as costimulatory domains fused to the CD3ζ signaling moiety.